Key result
Patients with cancer-associated thrombosis prioritized anticoagulants with minimal interference with cancer treatment (39%), low thrombosis recurrence (24%), and low major bleed risk (19%).
Why the study?
What features are most important to patients with cancer-associated thrombosis regarding their choice of anticoagulant?
Cross-Sectional (n=109)
What features are most important to patients with cancer-associated thrombosis regarding their choice of anticoagulant?
Patients with cancer-associated thrombosis prioritize anticoagulants that do not interfere with their cancer treatment and favor efficacy and safety over the convenience of oral administration.
No takes yet. Share an insight, caveat, or question.
May inform shared anticoagulant decisions; leaves open effects on adherence or outcomes.
Noble et al. (2015) conducted a cross-sectional in Cancer-associated thrombosis (n=109). Anticoagulant therapy was evaluated on Most important attributes of an anticoagulant. Patients with cancer-associated thrombosis prioritized anticoagulants with minimal interference with cancer treatment (39%), low thrombosis recurrence (24%), and low major bleed risk (19%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: